Page last updated: 2024-09-04

atazanavir and moexipril

atazanavir has been researched along with moexipril in 3 studies

Compound Research Comparison

Studies
(atazanavir)
Trials
(atazanavir)
Recent Studies (post-2010)
(atazanavir)
Studies
(moexipril)
Trials
(moexipril)
Recent Studies (post-2010) (moexipril)
75137992917

Protein Interaction Comparison

ProteinTaxonomyatazanavir (IC50)moexipril (IC50)
Angiotensin-converting enzyme Homo sapiens (human)0.0427
Angiotensin-converting enzyme 2 Homo sapiens (human)0.056

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Abbenante, G; Fairlie, DP; Leung, D1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1

Reviews

2 review(s) available for atazanavir and moexipril

ArticleYear
Protease inhibitors: current status and future prospects.
    Journal of medicinal chemistry, 2000, Feb-10, Volume: 43, Issue:3

    Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors

2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

1 other study(ies) available for atazanavir and moexipril

ArticleYear
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023